News

June 1, 2017

European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union

European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union

Biogen announced today that the European Commission (EC) has granted a marketing authorization for Spinraza for the treatment of spinal...

READ MORE   |  

Topics: Front Page News

May 30, 2017

Cure SMA Awards $140,000 Grant to Oliver Gruss, PhD, Rheinische Friedrich-Wilhelms-Universitat Bonn and Utz Fischer, PhD, Julius-Maximilians-Universitat Wurzburg, Germany

Cure SMA Awards $140,000 Grant to Oliver Gruss, PhD,  Rheinische Friedrich-Wilhelms-Universitat Bonn and Utz Fischer, PhD, Julius-Maximilians-Universitat Wurzburg, Germany

Cure SMA has awarded a $140,000 research grant to Drs. Oliver Gruss and Utz Fischer at Rheinische Friedrich-Wilhelms-Universitat Bonn and Julius-Maximilians-Universitat Wurzburg in Germany to study “Regulatory cues modulating the activity of SMN in human cells.”

This...

READ MORE   |  

Topics: Research, Front Page News

May 19, 2017

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Cytokinetics, Inc. recently announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-2127107, a next-generation fast skeletal muscle activator, for the potential treatment of spinal muscular...

READ MORE   |  

Topics: Clinical Trials, Front Page News

Items 19 - 21 of 365  Previous12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software